RxDoctor Payments Data

Henry Su, MD

Infectious Disease · Long Beach, CANPI 1902033913

Payments from drug & device makers

$4,934in general payments, 2019–2025

Across 253 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Merck$587
  • Gilead$584
  • AbbVie$514
  • Johnson & Johnson$495
  • Shionogi Inc$401
  • plus $1K from 11 others

What the payments were for

  • Speaking & faculty fees$210%
  • Food & beverage$4,32888%
  • Education$58412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,934 in reported general payments places this provider in the 70th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$116,704
Medicare patients
299
Services billed
958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala61$283,212
DovatoDolutegravir Sodium/Lamivudine44$144,811
GenvoyaElviteg/Cob/Emtri/Tenof Alafen26$110,977
CabenuvaCabotegravir/Rilpivirine18$98,824
DescovyEmtricitabine/Tenofov Alafenam42$89,964
Egrifta SvTesamorelin Acetate12$80,334
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf17$79,823
TivicayDolutegravir Sodium21$45,117
JulucaDolutegravir/Rilpivirine11$41,826
PrezcobixDarunavir/Cobicistat13$30,283
IsentressRaltegravir Potassium13$25,447
Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod28$5,901
Ethambutol Hcl13$1,299
Cefpodoxime Proxetil14$1,165
Rifampin13$746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$584$484,152129 claims
Viiv Healthcare CompanyDovato, Cabenuva, Tivicay, Juluca$1,065$330,57894 claims
Theratechnologies Inc.Egrifta Sv$64$80,33412 claims
Janssen Products, LPSymtuza$129$79,82317 claims
Johnson & JohnsonPrezcobix$495$30,28313 claims
MerckIsentress$587$25,44713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 856 infectious disease providers in California.

Other infectious disease in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →